Sandoz Files US Generic Tirzepatide Applications; Canada Watches

Swiss pharmaceutical manufacturer Sandoz has had two applications accepted by the U.S. Food and Drug Administration for proposed generic versions of tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review].

What Sandoz filed

The FDA has agreed to review Sandoz's applications for two proposed generic tirzepatide products, both intended as weekly injections [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review]. The FDA typically completes reviews of standard drug applications within 10 months, though the agency has not specified a timeline for these particular files [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review].

Sandoz has estimated its products would cost between $200 and $400 per month without insurance in the U.S., compared with brand-name Mounjaro and Zepbound, which the article states can cost more than $1,000 per month uninsured [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review].

Claire D'Abreu-Hayling, president of Generics Development and chief scientific officer at Sandoz, said in a press statement that "Sandoz is building its GLP-1 development platform, and this submission reflects true in-house innovation" [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review].

US patent wall versus other markets

Eli Lilly holds patent protection for Mounjaro and Zepbound in the United States until 2036, meaning generic tirzepatide cannot be sold in the U.S. until the patent expires unless a company obtains special permission from the FDA or a court [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review]. Healthline notes that tirzepatide patents are expiring in other countries, prompting an intense race among pharmaceutical companies to enter the GLP-1 market outside the United States [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review].

Canadian context: semaglutide moved first

Healthline notes that in June, Canadian health officials approved a generic version of Novo Nordisk's Wegovy, an injectable manufactured by Canada-based Apotex under the brand Sevian [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review]. Wegovy contains semaglutide, the same active ingredient as Ozempic and Rybelsus.

For Canadian purchasers tracking tirzepatide specifically, current pharmacy prices catalogued on GLP1Prices.ca range from CAD $149 to $800 for Mounjaro and CAD $276 to $612.81 for Zepbound. The Sandoz US price estimate of $200-$400 was cited in USD for the U.S. market only [Source: healthline.com/health-news/generic-mounjaro-zepbound-application-review], and does not translate directly to Canadian pharmacy shelf prices.

Counterfeit warning still active

As interest in GLP-1 products grows, Health Canada continues to warn against unauthorized and counterfeit versions of semaglutide and tirzepatide products [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized]. The advisory, last updated 2026-01-21, states that Health Canada has identified various retailers in Canada selling unauthorized GLP-1 products both in stores and online, and that some websites and social media advertisements misuse official Health Canada logos and display fake endorsements [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized].

Health Canada advises consumers to buy prescription drugs only from licensed pharmacies and to verify products by checking the eight-digit Drug Identification Number (DIN) on the label against Health Canada's Drug Product Database [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized]. The agency notes it is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country [Source: recalls-rappels.canada.ca/en/alert-recall/thinking-about-buying-glp-1-drugs-ozempic-or-mounjaro-beware-fake-or-unauthorized].

• Confirm the DIN on any GLP-1 product label
• Purchase only from licensed Canadian pharmacies
• Report suspected counterfeit products to Health Canada

What Canadian buyers can do now

The Sandoz filings are with the U.S. FDA and do not represent a Canadian regulatory decision on tirzepatide generics. Canadians tracking approvals and pricing can use the generic semaglutide tracker, review private-plan coverage via the insurance coverage checker, or consult the FAQ for status updates on brand and generic products in Canada.

This article is for informational purposes only and does not constitute medical advice.